Cubist shelves ecallantide program

Cubist Pharmaceuticals is shelving its program for ecallantide, a once promising therapy for reducing blood loss in surgery, and axing its development deal on the drug with Dyax. The troubled program was suspended in mid-stage late last year after researchers spotted a higher death rate among patients taking the drug. Story

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.